The use of real world data to assess the safety and effectiveness of drugs and medical treatments is among the most controversial topics in medicine. As chief executive of Aetion, a New York City startup that sells software to analyze those data, Carolyn Magill is in the middle of the fray — one whose outcome will have a huge impact on how medicines are studied and priced in the future.

During an interview with STAT at last week’s Health Datapalooza conference in Washington, D.C., the former insurance executive passionately made the case that analyzing real world data is crucial for incorporating patient experiences into decision-making by drug companies, insurers, providers, and regulators.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy